On Demand Wednesday Lecture Series: Research with Psilocybin: History, Neuropharmacology, and Potential Clinical Applications
This presentation was originally reviewed on December 2, 2021, and broadcast live online on June 26, 2019 from 12:00 noon - 1:00 PM ET.
The views and opinions expressed by this presenter in this lecture are their own, and do not represent the views of Sheppard Pratt.
Psilocybin is a classic psychedelic compound that may have efficacy for the treatment of mood and substance use disorders. Acute psilocybin effects include reduced negative mood, increased positive mood, and reduced amygdala response to negative affective stimuli. This presentation will discuss the positive enduring changes reported by clinical participants after psilocybin exposure, enduring impairing psychiatric conditions, as well as the most promising therapeutic indications for this treatment,
This activity is intended for physicians, nurses, psychologists, social workers, counselors, therapists and other mental health professionals.
At the conclusion of this activity, attendees will be able to:
1. Identify some of the effects and risks of psilocybin administration.
2. Recognize some of the effects of psilocybin.
3. Discuss the most promising therapeutic indications for which preliminary research suggests that psilocybin may be efficacious.
Sheppard Pratt’s Professional Education Program is pleased to provide Wednesdays at Sheppard Pratt free of charge as a public service to the mental health community. Your tax-deductible donations will help maintain the outstanding quality of this service.
Sheppard Pratt is dedicated to improving quality of life through mental health, special education, and addiction services for children, adolescents, adults and older adults. Our patient-centered treatment approach, combined with our legacy of clinical excellence, sets us apart from other health systems on both a local and national level. We have been ranked among the nation’s top psychiatric hospitals for 24 consecutive years by U. S. News & World Report. Founded in 1853 by philanthropist Moses Sheppard, Sheppard Pratt Health System still abides by its Quaker traditions and values.
Sheppard Pratt regularly hosts renowned speakers from across the country at our headquarters in Towson. We provide educational opportunities on subjects including psychiatric disorders, issues of behavioral health, systems-based change, mental and somatic co-morbidities, psychiatric effects on health and health outcomes, advances in neurobiology, and clinical developments in concepts underlying drug treatment of psychiatric disorders. We are accredited by the Accreditation Council of Continuing Medical Education, the Maryland Nurses’ Association, the Maryland Board of Psychology, the Maryland Board of Social Work, and the National Board of Certified Counselors.
Please send your contributions to:
Sheppard Pratt Professional Education Program
Wednesdays Lecture Fund
6501 North Charles Street, Baltimore, Maryland 21204
Professional Education Program: 410.938.4593
Conference Center at Sheppard Pratt: 410.938.3900
There is no commercial support for this activity.
About This Speaker
Roland Griffiths, Ph.D., is a Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins School of Medicine whose research has focused on the behavioral and subjective effects of mood-altering drugs. His research has been largely supported by grants from the National Institutes of Health, and he is author of over 370 scientific publications. He has conducted extensive research with sedative-hypnotics, caffeine, and novel mood-altering drugs. In 1999 he initiated a research program investigating the effects of the classic psychedelic psilocybin that includes studies in healthy volunteers, in beginning and long-term meditators, and in religious leaders. Therapeutic studies with psilocybin include treatment of psychological distress in cancer patients, treatment of cigarette smoking cessation, and psilocybin treatment of major depression. Planned future studies include assessing psilocybin effects in early Alzheimer's Disease and a study of psilocybin treatment of anorexia. Brain imaging studies (fMRI and PET) are providing insight into the underlying neural effects that account for unique features of psychedelic experiences. The Hopkins laboratory has also conducted a series of internet survey studies characterizing unusual psychedelic experiences including mystical-type, challenging, and near-death like experiences.
Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she (or a partner or spouse) has with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt Health System, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.
Roland R. Griffiths, Ph.D., reports that he has no relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 12 months. He will discuss any products, services, or off-label uses in this presentation.
Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months: Todd Peters, MD, Deepak Prabhakar, MD, Briana Riemer, MD, Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PhD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Laura Webb, RN-BC, MSN, Bruce Boxer, PhD, MBA, MA, MSN, RN, NPD-BC, NEA-BC, MCHES, CPHQ, Stacey Garnett, RN, MSN, Heather Billings, RN, and Jennifer Tornabene.
Physician Statement: Sheppard Pratt is accredited by The Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. Sheppard Pratt designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Statement: Sheppard Pratt is an approved provider of continuing nursing education by Maryland Nurses Association. The Maryland Nurses Association is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity provides 1.0 contact hours for nurses.
Psychologist Statement: Sheppard Pratt is authorized by the State Board of Examiners of Psychologists as a sponsor of continuing education. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CE activity. Sheppard Pratt designates this educational activity for a maximum of 1.0 contact hours for Psychologists.
Social Worker Statement: Sheppard Pratt is authorized by the Board of Social Work Examiners of Maryland to offer continuing education for Social Workers. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CE activity. This activity is approved for 1.0 contact hours in Category II credits for Social Workers.
Counselor Statement: Sheppard Pratt has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5098. Programs that do not qualify for NBCC credit are clearly identified. Sheppard Pratt is solely responsible for all aspects of the program. This activity is available for 1.0 NBCC clock hours.
- 1.00 ACEP NBCC clock hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Category II credits for Social Workers
- 1.00 Psychologists
- 1.00 MNA Contact Hours for Nurses
- 1.00 Participation
ON DEMAND WEBINAR: FOR BEST RESULTS WATCH USING GOOGLE CHROME
Wednesday Lecture Series: Wednesday Lecture Series: Research with Psilocybin: History, Neuropharmacology, and Potential Clinical Applications
Ronald R. Griffiths, Ph.D.
The Oliver Lee McCabe, III Professor in the Neuropsychopharmacology of Consciousness
Professor of Psychiatry and Behavioral Sciences
Originally reviewed December 2, 2021.
Originally broadcast live June 26, 2019, from 12:00 noon - 1:00 pm ET
Enduring Activity Credit Expiration Date: April 16, 2024
Activity Time: One hour recorded webinar lecture with a 15-minute evaluation process. Total Time: 1:15
TO EARN CONTINUING EDUCATION CREDIT FOR YOUR ATTENDANCE
On the OVERVIEW or REGISTER/TAKE COURSE tab, select the GREEN RECTANGLE, TAKE COURSE to begin.
Complete the Pretest and select NEXT in the bottom right corner of the screen. Use the NEXT button for best results.
The PowerPoint handout will be available for download.
After downloading the handout, select NEXT to begin and watch the one-hour video.
You may need to select play for the video to begin.
After the video follow the prompts to complete the posttest, evaluation and attestation of credit.
Once you have completed all the components of the Course Progress bar, the certificate will be immediately downloadable.
There is no commercial support for this activity.
Questions? Please email firstname.lastname@example.org.
Optimal System Configuration
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit